Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 75.73K.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 75.73K.
Subavaliada
O PE mais recente da empresa é -0.55, em uma faixa percentil baixa de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 58.05K ações, um aumento de 22.32% em relação ao trimestre anterior.